CD8A and neoplasm: As a final test to assess whether cross-presentation of palmitoylated synthetic long peptides to CD8+ T cells would lead to increased tumor cell killing in vivo, B16-OVA tumor cells were injected s.c. into immunocompetent C57BL/6 mice.